Top Markets
#1 EXOD EXOD +56.80%
#2 MowCat MowCat +48.16%
#3 Glidr Glidr +36.87%
#4 CoW Protocol CoW Protocol +36.53%
#5 RedStone RedStone +28.90%
#6 Humanity Humanity +26.35%
#7 Codatta Codatta +22.55%
#8 Walrus Walrus +19.98%
#9 The Black Bull The Black Bull +17.02%
#10 Enso Enso +16.70%
Coin of the day
EXOD EXOD
Instellingen
Taal
DUTCH
Valuta
USD
Thema
Carmell Therapeutics Corporation Carmell Therapeutics Corporation

Carmell Therapeutics Corporation

CTCX
Rang in aandelen #36666
Carmell Therapeutics Corporation (CTCX) specializes in the creation of... Carmell Therapeutics Corporation (CTCX) specializes in the creation of plasma-based bioactive materials (PBMs) aimed at catalyzing tissue regeneration and repair following injury, illness, or the effects of aging. Their flagship product, CT-101, is a versatile accelerant with a dual focus. For orthopedic and dental applications, it's designed to enhance bone healing in cases such as tibia fractures, foot and ankle fusions, spinal fusions, and also serves as a dental bone graft substitute and bone void filler. Furthermore, CT-101 acts as a tissue healing accelerant, addressing conditions like androgenetic alopecia (pattern baldness) and persistent chronic wounds. Established in 2008, the company operates from its headquarters in Pittsburgh, Pennsylvania.
Aandeelprijs
$0.117
Laatst gesynchroniseerd: 2025-04-04
Marktkapitalisatie
$2.45M
Verandering (1 dag)
-13.59%
Verandering (1 jaar)
0.00%
Land
US
Handel Carmell Therapeutics Corporation (CTCX)

Categorie

Healthcare
P/S-ratio voor Carmell Therapeutics Corporation (CTCX)
P/S-ratio op August 2026 TTM: 3.52
Volgens de meest recente financiële rapporten en aandelenkoers van Carmell Therapeutics Corporation is de huidige P/S-ratio (TTM) 3.52. Eind 2023 had het bedrijf een P/S-ratio van 0.00.
P/S-ratiohistoriek voor Carmell Therapeutics Corporation van 2021 tot 2026
P/S-ratio aan het einde van elk jaar
Jaar P/S-ratio Wijzigen
2026 (TTM) 3.52 -99.90%
2024 3.48K 0.00%
2023 0.00 0.00%
2022 0.00 0.00%
2021 0.00 0.00%
P/S-ratio voor vergelijkbare bedrijven of concurrenten
Bedrijf P/S-ratio Verschil in P/S-ratio Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
10.17 188.58%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
10.13 187.49%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
4.74 34.60%
BE